Dyne Therapeutics (DYN) Interest Expenses (2019 - 2026)
Dyne Therapeutics (DYN) posted quarterly Interest Expenses of $88.7 million for Q2 2026, up 79.66% quarter-over-quarter from $49.4 million in Q1 2026.
Dyne Therapeutics (DYN) Interest Expenses (2019 - 2026) Analysis & Trends
Dyne Therapeutics (DYN) has reported Interest Expenses for 8 consecutive years, with $88.7 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Interest Expenses changed N/A year-over-year to $88.7 million; the TTM figure through Jun 2026 stood at $88.7 million (up 1611.42% YoY), while the FY2025 annual figure was $419.2 million, up 45.23% from the prior year.
- Interest Expenses improved to $88.7 million in Q2 2026 per DYN's latest filing, from $49.4 million in the prior quarter.
- Across five years, Interest Expenses topped out at $178.0 million in Q2 2024 and bottomed at $2.5 million in Q4 2025.
- Historically, Interest Expenses has averaged $55.1 million across 5 years, with a median of $29.3 million in 2023.
- Annual changes were most pronounced in 2022 — Interest Expenses soared 55871.43% — and 2024, when it tumbled 96.58%.
- Dyne Therapeutics' Interest Expenses stood at $113.6 million in 2022, then increased by 28.3% to $145.8 million in 2023, then sank by 96.58% to $5.0 million in 2024, then sank by 48.89% to $2.5 million in 2025, then jumped by 3384.68% to $88.7 million in 2026.
- Business Quant data shows DYN's Interest Expenses at $88.7 million in Q2 2026, $49.4 million in Q1 2026, and $2.5 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 439.40 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 52.50 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.70 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 39.74 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 335,572.77 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 218.10 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 82.05 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 20.27 Mn |
| 10 | Dyne Therapeutics | 4.26 Bn | 4.26 Bn | - | 88.72 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 88.72 Mn |
| Jun 30, 2026 | 88.72 Mn |
| Mar 31, 2026 | 49.38 Mn |
| Mar 31, 2026 | 49.38 Mn |
| Dec 31, 2025 | 2.55 Mn |
| Dec 31, 2025 | 2.55 Mn |
| Sep 30, 2025 | 2.90 Mn |
| Sep 30, 2025 | 2.90 Mn |
| Mar 31, 2025 | 6.55 Mn |
| Mar 31, 2025 | 6.55 Mn |
| Dec 31, 2024 | 4.98 Mn |
| Dec 31, 2024 | 4.98 Mn |
| Jun 30, 2024 | 178.02 Mn |
| Jun 30, 2024 | 178.02 Mn |
| Mar 31, 2024 | 133.49 Mn |
| Mar 31, 2024 | 133.49 Mn |
| Dec 31, 2023 | 145.78 Mn |
| Dec 31, 2023 | 145.78 Mn |
| Sep 30, 2023 | 15.51 Mn |
| Sep 30, 2023 | 15.51 Mn |